Takeda and ImmunoGen partner to develop and commercialise Elahere in Japan
ImmunoGen is expected to receive an upfront payment from Takeda plus additional payment
Read Moreby Jen Brogan | Aug 29, 2023 | News | 0
ImmunoGen is expected to receive an upfront payment from Takeda plus additional payment
Read Moreby John Pinching | Jan 20, 2023 | News | 0
Therapy involves patients living with relapsed or refractory multiple myeloma
Read Moreby John Pinching | Nov 22, 2022 | News | 0
Research from Takeda and Institute Krems Bioanalytics of IMC Krems and will help treat patients
Read Moreby John Pinching | Jun 9, 2022 | News | 0
Vital dengue vaccine offers over four years’ protection following successful clinical trial
Read Moreby John Pinching | Apr 12, 2022 | News | 0
Engitix and Takeda will extend existing agreement to collaborate extensively in the development of therapeutics in IBD
Read Moreby John Pinching | Mar 21, 2022 | News | 0
Patients eligible to receive Takeda’s Exkivity (mobocertinib) have a rare form of lung cancer that cannot be removed by surgery
Read Moreby Lucy Parsons | Sep 3, 2021 | News | 0
Pevonedistat plus azacitidine did not meet primary endpoint of EFS
Read Moreby Lucy Parsons | Aug 11, 2021 | News | 0
The clinical development programme is now known as TAK-524
Read Moreby Lucy Parsons | May 25, 2021 | News | 0
Vaccine candidate demonstrated 83.6% efficacy against hospitalisation three years after vaccination
Read Moreby Selina McKee | Dec 15, 2020 | News | 0
A new report launched by Takeda has found that just 17% of UK adults surveyed felt their perception of pharma had improved based on the industry’s response to COVID-19
Read Moreby Lucy Parsons | Dec 10, 2020 | News | 0
Follows previous agreements signed in November 2018 and July 2019
Read Moreby Selina McKee | Aug 26, 2020 | News | 0
The firms will use Engitix’ extracellular matrix (ECM) discovery platform to develop new therapies for fibrotic liver diseases
Read More





PharmaTimes Media Ltd.
44 Maiden Lane
Covent Garden
London
WC2E 7LN
E: editorial@pharmatimes.com
E: subscriptions@pharmatimes.com
T: +44 (0)20 7240 6999
